TOPLINE:

Among adults treated with adalimumab, those with hidradenitis suppurativa (HS) showed a 53% higher risk for serious infections than adults with psoriasis, with notably increased risks for sepsis and genitourinary infections.

METHODOLOGY:

Researchers conducted a retrospective cohort study of 10,349 adults (mean age, 44.8 years; 54.5% women) with HS (n = 1650) or psoriasis (n = 8699) from the MarketScan database who initiated treatment with adalimumab between January 2017 and December 2020.

Patients with HS were younger (mean age, 36.2 vs 46.5 years), mostly women (77% vs 50.2%), and had higher rates of obesity, Crohn’s disease, anxiety, and depression than those with psoriasis.

The primary outcome was hospitalization for noncutaneous infections. Secondary outcomes included inf

See Full Page